Institutional members access full text with Ovid®

Share this article on:

Single donor versus pooled random donor platelet concentrates

Ness, Paul M. MD*†; Campbell-Lee, Sally A. MD

Current Opinion in Hematology: November 2001 - Volume 8 - Issue 6 - p 392-396
Transfusion medicine

Both platelet concentrates (PC) derived from whole blood or single donor platelets (SDP) obtained from a single donor by apheresis are indicated to treat acute hemorrhage secondary to thrombocytopenia or to provide prophylaxis from hemorrhage in patients with bone marrow aplasia. Currently platelet transfusion therapy is limited by several concerns, including the consequences of alloimmunization in chronically transfused patients and septic reactions caused by bacterial contamination. There is debate about which platelet product should be used; many transfusion services favor the primary use of PC, whereas others favor SDP. This review will discuss five areas that should be considered when considering the use of SDP or PC: (1) the impact on infectious complications, (2) transfusion reaction rate, (3) leukodepletion, (4) reduction of transfusion frequency in patients with bone marrow suppression and, (5) the treatment and prevention of alloimmunization. The authors believe that SDP offers major advantages over PC for most of these issues, particularly when improved patient care is given primary emphasis.

*Greater Chesapeake and Potomac Blood Services Region, American Red Cross, and Division of Transfusion Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

Correspondence to Paul M. Ness, MD, Division of Transfusion Medicine, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD, 21287 USA; e-mail:

© 2001 Lippincott Williams & Wilkins, Inc.